ClinicalTrials.gg

Program

tersolisib

Also written as “LY4064809”, “Tersolisib” and “STX-478”.

Its studies are mostly in Breast Neoplasms · Renal Insufficiency, led by Eli Lilly.

Furthest: phase 3, since Sep 12, 202510 company-led studies, 4 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly104 open or runningphase 3since Sep 12, 2025Mar 1, 2023Aug 2027phase 1 · NCT07924930
  • Named in Eli Lilly’s own pipeline as Tersolisib, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2023First study: phase 2 study in Breast NeoplasmsFirst studyNCT05768139 · 880 planned · United States, Belgium, France and more
  2. Mar 24, 2025Phase 1 study in HealthyNCT06901336 · 8 enrolled · United States
  3. May 19, 2025Phase 1 study in HealthyNCT06991179 · 36 enrolled · United States
  4. Sep 12, 2025Phase 3 study in Breast NeoplasmsNCT07174336 · 800 planned · United States, Argentina, Australia and more
  5. Nov 18, 2025Phase 1 study in HealthyNCT07247357 · 10 enrolled · Singapore
  6. Jan 6, 2026Phase 1 study in Healthy ParticipantsNCT07339735 · 24 enrolled · United States
  7. Mar 30, 2026Phase 1 study in HealthyNCT07519525 · 7 enrolled · United States
  8. Jun 17, 2026Phase 1 study in HealthyNCT07662798 · 60 enrolled · United States
  9. Nov 4, 2026Phase 1 study in Renal InsufficiencyNCT07924930 · 32 planned · United States
  10. Nov 9, 2026Phase 2 study in Breast NeoplasmsNCT07935317 · 120 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07924930
  2. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07935317
  3. May 2029Primary completion: phase 3 study in Breast NeoplasmsNCT07174336
  4. Jul 2030Primary completion: phase 2 study in Breast NeoplasmsNCT05768139

TargetBeta

“An orally bioavailable, brain penetrative, selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha) mutant H1047X, with potential antineoplastic activity. Upon oral administration, te…”NCIt, read by Claude
“An orally bioavailable, brain penetrative, selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha) mutant H1047X, ”NCIt, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935317Breast Neoplasms · United States2Not yet recruitingDec 2027120
NCT07924930Renal Insufficiency · United States1Not yet recruitingAug 202732
NCT07662798Healthy · United States1CompletedSep 3, 202660
NCT07519525Healthy · United States1CompletedMay 26, 20267
NCT07339735Healthy Participants · United States1CompletedMar 19, 202624
NCT07247357Healthy · Singapore1CompletedDec 16, 202510
NCT07174336Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMay 2029800
NCT06991179Healthy · United States1CompletedSep 2, 202536
NCT06901336Healthy · United States1CompletedMay 6, 20258
NCT05768139Breast Neoplasms · United States, Belgium, France and more2RecruitingJul 2030880

How it is read

Names in the registry

  • “LY4064809”, 4 entries
  • “Tersolisib”, 3 entries
  • “STX-478”, 1 entry
  • “LY4064809 Test Formulation”, 1 entry
  • “LY4064809 Reference Formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.